- Published at
- by gurufocus.com
positive
positive
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit
PR NewswireNEW YORK, May 12, 2025
NEW YORK, May 12, 2025 /PRNewswire/ --
News for Actinium Pharmaceuticals, Inc. (ATNM)
- Published at
- by gurufocus.com
neutralneutralINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
PR NewswireNEW YORK, May 12, 2025 NEW YORK, May 12, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Actiniu- Published at
- by gurufocus.com
neutralneutralActinium Pharma (ATNM) Receives Buy Rating with $4.00 Price Target | ATNM Stock News
On May 12, 2025, Actinium Pharma (ATNM) received attention from HC Wainwright & Co., as analyst Joseph Pantginis reiterated a 'Buy' rating for the company. The- Published at
- by gurufocus.com
negativenegativeActinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before May 27, 2025 to Discuss Your Rights - ATNM
PR NewswireNEW YORK, May 12, 2025 NEW YORK, May 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmac- Published at
- by markets.businessinsider.com
negativenegativeActinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ATNM
NEW YORK, NY / ACCESS Newswire / May 11, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to l...- Published at
- by gurufocus.com
neutralneutralINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (”Actin- Published at
- by gurufocus.com
neutralneutralActinium Pharmaceuticals (ATNM) Begins Pioneering Iomab-ACT Trial with CAR-T Therapy | ATNM Stock News
Actinium Pharmaceuticals (ATNM) has initiated a significant clinical trial involving their Iomab-ACT targeted conditioning agent. The first patient has been enr- Published at
- by gurufocus.com
positivepositiveActinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center | ATNM Stock News
Actinium Pharmaceuticals (ATNM) initiates groundbreaking trial with the enrollment of the first patient for Iomab-ACT at the University of Texas Southweste- Published at
- by gurufocus.com
neutralneutralINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
PR NewswireNEW YORK, May 6, 2025 NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Actinium- Published at
- by gurufocus.com
neutralneutralKirby McInerney LLP Urges Investors in Actinium Pharmaceuticals, Inc. (ATNM) to Inquire About Their Rights in Class Action Lawsuit
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. Distri- Published at
- by gurufocus.com
mixedmixed- Published at
- by gurufocus.com
positivepositiveActinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy
PR NewswireNEW YORK, March 20, 2025 NEW YORK, March 20, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company)- Published at
- by gurufocus.com
mixedmixedActinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®
PR NewswireNEW YORK, March 18, 2025 - Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA® or OPDIVO® can resul- Published at
- by gurufocus.com
positivepositiveActinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia
PR NewswireNEW YORK, March 17, 2025 - Median Overall Survival of 18.4 months with Actimab-A + CLAG-M in patients with relapsed or refractory AML who- Published at
- by gurufocus.com
positivepositiveActinium Pharmaceuticals to Participate at the 37th Annual Roth Conference
PR NewswireNEW YORK, March 12, 2025 NEW YORK, March 12, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company)- Published at
- by rttnews.com
negativenegativeActinium Pharma Q3 Loss Narrows
Actinium Pharmaceuticals Inc. (ATNM) Monday announced a narrower loss for the third quarter. The September quarter loss was $11.6 million, compared to $13.3 million a year ago.- Published at
- by gurufocus.com
neutralneutralActinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024
PR NewswireNEW YORK, Nov. 18, 2024 - Aligned with FDA on operationally seamless Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory acute myeloi- Published at
- by globenewswire.com
mixedmixedRadiopharmaceuticals Market Size Projected to Soar to USD 16.6 Billion by 2032 with 10.4% CAGR – SNS Insider
According to Research by SNS Insider, The Radiopharmaceuticals Market growth is driven by advancements in nuclear medicine, personalized treatments, and...- Published at
- by rttnews.com
mixedmixedWeekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal Spray
The week saw FDA reprimanding a pharma giant for making false and misleading claims about its non-small cell lung cancer drug and a developer of MDMA therapy for PTSD facing a major setback.- Published at
- by benzinga.com
mixedmixedWhy Palantir Technologies Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket - Palantir Technologies (NYSE:PLTR)
Shares of Palantir Technologies Inc PLTR rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter results. Pal...